CK
MRNA icon

Cohen Klingenstein’s Moderna MRNA Stock Holding History

Cohen Klingenstein’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,100
Closed -$249K – 222
2024
Q2 		$249K Hold
2,100
– – 0.01% 219
2024
Q1 		$224K Hold
2,100
– – 0.01% 220
2023
Q4 		$209K Hold
2,100
– – 0.01% 219
2023
Q3 		$217K Hold
2,100
– – 0.01% 219
2023
Q2 		$255K Hold
2,100
– – 0.01% 215
2023
Q1 		$323K Hold
2,100
– – 0.02% 207
2022
Q4 		$377K Hold
2,100
– – 0.02% 200
2022
Q3 		$248K Hold
2,100
– – 0.01% 216
2022
Q2 		$300K Hold
2,100
– – 0.02% 212
2022
Q1 		$362K Hold
2,100
– – 0.02% 211
2021
Q4 		$533K Sell
2,100
-25
-1% -$7.31K 0.02% 192
2021
Q3 		$818K Buy
+2,125
New +$784K 0.04% 193

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cohen Klingenstein's MRNA Position: Q3 2024 in Review

Cohen Klingenstein sold out of Moderna (MRNA) in Q3 2024, closing a stake of 2,100 shares — an estimated $249K sold.

Cohen Klingenstein first reported a position in MRNA in Q3 2021 and held it in 12 quarters. The position peaked at $818K in Q3 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Cohen Klingenstein reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Cohen Klingenstein sold 2,100 Moderna shares in Q3 2024, an estimated $249K.
  • Cohen Klingenstein first reported a position in Moderna in Q3 2021 and held it in 12 quarters.
  • Cohen Klingenstein's Moderna position peaked at $818K in Q3 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Cohen Klingenstein's 13F filing for Q3 2024, filed 16 Oct 2024.